Compare abrdn Income Credit Strategies Fund (ACP) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Koninklijke Philips NV — how do they compare? abrdn Income Credit Strategies Fund trades at $5.23 (market cap $656.21M), while Koninklijke Philips NV trades at $27.58 (market cap $27.30B). The key difference: Koninklijke Philips NV is far larger — about 41.6× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays the higher dividend (17.78%). Which is the better fit depends on your goals.
| ACP | PHG | |
|---|---|---|
Market Cap | $656.21M | $27.30B |
Sector | Financials | Health |
52-Week High | $5.98 | $32.91 |
52-Week Low | $5.01 | $24.03 |
Dividend Yield | 17.78% | 3.59% |
Enterprise Value | — | $33.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.25, down 0.57% today, with a neutral technical signal. The stock shows a low P/B of 0.89 and a high net income margin of 95.51% for 2024, though revenue declined from $79M in 2024 to $42M in 2025. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns. Cash flow from operations was negative $81.31M in 2024, offset by financing inflows.
Outlook is mixed: valuation appears modest with a P/E near 16, but declining revenue and negative operating cash flow pose risks. The 17% distribution rate faces sustainability questions, while technical indicators suggest limited near-term momentum. Investors should weigh income potential against fundamental weaknesses and high beta exposure.
PHG trades at $28.23, up 1.77% with a bullish technical outlook supported by moving averages. The company shows improved profitability with net income turning positive at $895 million in 2025 after previous losses. Recent earnings beat expectations in two of the last three quarters, while analyst sentiment leans neutral with 40.9% buy ratings. Strong cash flow generation and strategic partnerships in healthcare technology position the company for continued recovery.
The stock presents a recovery story with improving fundamentals but faces execution risks in a competitive healthcare technology market. Valuation appears reasonable with P/E of 24.73 and P/S of 1.35, though debt levels remain elevated. Near-term catalysts include Q2 2026 earnings and continued AI integration in healthcare solutions, while macroeconomic pressures and competitive threats represent ongoing challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
